Paliperidone palmitate
Onset of efficacy and tolerability following the initiation dosing of long acting paliperidone palmitate: post hoc analyses of a randomized, double blind clinical trial
... One must also consider that this study was not designed to assess onset of efficacy or the tolerability associated with the initiation regimen. Therefore, these findings are somewhat limited by the timepoints that were ...
10
Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies
... once-monthly paliperidone palmitate (PP) against oral paliperidone extended release (ER) using indirect comparative techniques and subject-level data from two similarly designed maintenance treatment ...
9
Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
... peridone palmitate and among the active entities of their oral and injectable formulations, questions may be raised about the efficacy of RLAI and paliperidone palmitate in subjects who have recently ...
10
Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial
... three paliperidone palmitate groups (note that per the study design the paliperidone palmitate groups were pooled for days 4 and 8) with the placebo group at baseline at each time point ...
10
Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long acting injections
... gredient paliperidone palmitate and Drug Production of the PP1M and PP3M syringes was retrieved from Batch Production Reports, Cleaning Procedures, Equipment Manuals, yearly planning and partly through a ...
16
Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose
... Background: Paliperidone palmitate (PP) is a long-acting injectable formulation of an atypical antipsychotic, ...active paliperidone (39, 78, 117, 156, and 234 mg of PP correspond to 25, 50, 75, 100, ...
10
Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
... to paliperidone palmitate at 78 mg (50 mg eq) on days 1 and 8, followed by flexible dosing of 39, 78, or 156 mg (25, 50, or 100 mg eq) at week 5; an open-label 24-week maintenance phase with flexible ...
11
<p>Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia</p>
... relapses. Paliperidone palmitate 3-monthly (PP3M) formulation is the only available LAI antipsychotic that offers an extended 3-month window of stable plasma drug concentration, enabling only four ...
15
<p>Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting</p>
... Background: Antipsychotics are an effective treatment option for patients with schizophre- nia and several long-acting injectables (LAIs), including risperidone, olanzapine, paliperi- done, and aripiprazole are available ...
8
Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
... on paliperidone palmitate, the long-acting injectable (LAI) formulation of ...done palmitate, we review the randomized controlled trials, as well as pertinent observational, pragmatic studies for ...
19
Adherence, healthcare resource utilization and Medicaid spending associated with once monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia
... Although the determinants of non-adherence are numerous and complex, medication-related factors such as the choice of AP therapy and dosing frequency are among its important drivers [6, 10]. For example, long- acting ...
18
<p>Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia</p>
... long-term paliperidone palmitate once-monthly (PP1M) therapy in Chinese patients with recent-onset schizophrenia responding unsatisfactorily to previous oral ...
10
Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study
... Patients and methods: Of 1,429 patients who entered the open-label (OL) phase, 510 were East Asian (China: 296 [58%], Japan: 175 [34%], South Korea: 19 [4%] and Taiwan: 20 [4%]). In the 17-week OL phase, patients ...
15
Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
... Objective: To evaluate the efficacy, safety, and impact on hospitalizations of long-acting injectable paliperidone palmitate (PP) treatment, in patients with recent-onset sc[r] ...
12
Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia
... for paliperidone palmitate that evaluated the product’s efficacy and safety for acute treat- ment of patients with schizophrenia and no studies for any of the first-generation long-acting ...peridone ...
9
Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults
... either paliperidone palmitate or risperidone ...received paliperidone 234 mg via deltoid intramuscular route on day one, 156 mg on day eight, and then once-monthly flexible ...whereas ...
13
Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study
... of paliperidone palmitate (150 milligram equivalents [mg eq] [day 1], 100 mg eq [day 8], both deltoid injections; 75–150 mg eq, deltoid/gluteal injection) in Chinese patients with acute schizophrenia ...
10
The cost reduction in hospitalization associated with paliperidone palmitate in the People’s Republic of China, Korea, and Malaysia
... Paliperidone palmitate (PP) is an atypical antipsychotic medication indicated for ...schizophrenia. Paliperidone was approved by the Food and Drug Administration (FDA) in 2006 for the treatment of ...
6
Body mass index and metabolic parameters in patients with schizophrenia during long term treatment with paliperidone palmitate
... Paliperidone palmitate (PP), a long-acting injectable (LAI) administered once-monthly (after an initiation regimen of two injections: 150 milligram equivalents (mg ...
11
A one year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia
... PP: Paliperidone palmitate; PK: Pharmacokinetics; SD: Standard deviation; TEAEs: Treatment-emergent adverse events; LAI: Long-acting injectable; PANSS: Positive And Negative Syndrome Scale; BMI: Body mass ...
14